Comment on FR Doc # 2026-10128

Summary: The commenter, representing a business in the pharmaceutical manufacturing sector, argues that the proposed changes to quota applications will not be successful in meeting the DEA's goals. They suggest alternative methods for tracking domestic vs. international usage and request specific revisions to quota timing and production cycle time definitions to better prevent drug shortages.